Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2146-e2153
DOI: 10.1210/clinem/dgag126 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 20.03.2026. Verfasst von Mandour O Mandour und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge CB2 0QQ, UK. Hauptthemen laut MEDLINE: Tirzepatide, Lipodystrophy, Familial Partial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health Research, Wellcome Trust, NIHR Rare Disease Translational Research Collaboration.
Abstract (Originalsprache)
Background
Lipodystrophy syndromes (LD) are a group of rare conditions characterized by the generalized or partial absence and/or dysfunction of adipocytes. Due to the lack of fat storage capacity, excess lipid accumulates in other tissues, leading to severe insulin resistance. At present, effective therapeutic options remain limited, with metreleptin currently the only specific licensed treatment. To this end, we evaluated the therapeutic impact of tirzepatide in people with partial lipodystrophy (PLD).
Methods
This was a single-center, retrospective, observational study, including all patients with PLD treated with tirzepatide between January 2022 and September 2025.
Results
Forty patients with PLD were included FPLD1 like = 26 (65%), FPLD2 = 4 (10%), FPLD3 = 7 (17.5%), FPLD7 = 1 (2.5%), APLD = 1 (2.5%), unclassified = 1 (2.5%). 87.5% (n = 35) were female with a median age of 47 years (IQR 39—59) and a median BMI of 31.5 kg/m2 (IQR 27.3 to 35.5). After a median 9.5 month follow-up (IQR 7 to 11), marked reductions were seen in body weight from 91.0 kg (IQR 75.0 to 106.0) to 82.8 kg (IQR 69.0 to 93.4; P < .0001), in HbA1c from 65 mmol/mol (IQR 54.5 to 85) to 52 mmol/mol (IQR 39 to 62; P < .0001) and in serum triglycerides from 2.80 mmol/L (IQR 1.6 to 3.7) to 1.83 mmol/L (IQR 1.0 to 2.9; P = .0005). Daily insulin requirements fell from 177.5 IU (IQR 101.3 to 213.8) to 58.0 IU (IQR 0 to 112.5; P = .0028).
Conclusion
In patients with partial lipodystrophy, tirzepatide use resulted in substantial statistically significant reductions in weight, glycemic control, serum triglycerides, and daily insulin requirement. We recommend further prospective studies to support these findings and to evaluate its impact earlier in the course of the disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Cambridge CB2 0QQ, UK.
- National Severe Insulin Resistance Service, Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospitals NHS Trust, Cambridge CB2 0QQ, UK.
ORCID-Profile: Mandour O Mandour
Förderung
- National Institute for Health Research
- Wellcome Trust
- NIHR Rare Disease Translational Research Collaboration
- Cambridge Biomedical Research Centre
Zitieren
APA
Mandour, M. O., Stears, A., Van Der Klaauw, A., Flanagan, C., Gaff, L., Jenkins, C., & Savage, D. B. (2026). Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2146-e2153. https://doi.org/10.1210/clinem/dgag126
Vancouver
Mandour MO, Stears A, Van Der Klaauw A, Flanagan C, Gaff L, Jenkins C, et al. Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2146-e2153. doi:10.1210/clinem/dgag126
BibTeX
@article{Mandour2026,
author = {Mandour, Mandour O and Stears, Anna and Van Der Klaauw, Agatha and Flanagan, Catherine and Gaff, Lisa and Jenkins, Charlotte and Savage, David B},
title = {Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {9},
pages = {e2146--e2153},
doi = {10.1210/clinem/dgag126}
}
EUVIMED